Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review

IMPORTANCE: Compared with standard cytotoxic therapies, randomized immune checkpoint inhibitor (ICI) phase 3 trials reveal delayed benefits in terms of patient survival and/or long-term response. Such outcomes generally violate the assumption of proportional hazards, and the classical Cox proportion...

Descripción completa

Detalles Bibliográficos
Autores principales: Filleron, Thomas, Bachelier, Marine, Mazieres, Julien, Pérol, Maurice, Meyer, Nicolas, Martin, Elodie, Mathevet, Fanny, Dauxois, Jean-Yves, Porcher, Raphael, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693223/
https://www.ncbi.nlm.nih.gov/pubmed/34932105
http://dx.doi.org/10.1001/jamanetworkopen.2021.39573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693223/
https://www.ncbi.nlm.nih.gov/pubmed/34932105
http://dx.doi.org/10.1001/jamanetworkopen.2021.39573

Ejemplares similares